Yuxuebi tablet + Placebo tablet
ApprovedUNKNOWN 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Ankylosing Spondylitis
Conditions
Ankylosing Spondylitis
Trial Timeline
Jul 1, 2021 โ Jan 31, 2022
NCT ID
NCT04934059About Yuxuebi tablet + Placebo tablet
Yuxuebi tablet + Placebo tablet is a approved stage product being developed by China Resources Pharmaceutical Group for Ankylosing Spondylitis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04934059. Target conditions include Ankylosing Spondylitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04934059 | Approved | UNKNOWN |
Competing Products
20 competing products in Ankylosing Spondylitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab | Celltrion | Phase 1 | 33 |
| Infliximab | Celltrion | Phase 1 | 33 |
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| adalimumab | Eisai | Phase 3 | 77 |
| Ixekizumab + Placebo + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Tramadol /acetaminophen + Diclofenac | Johnson & Johnson | Approved | 85 |
| Golimumab + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Golimumab | Johnson & Johnson | Approved | 85 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 2/3 | 65 |
| placebo for risankizumab + risankizumab | AbbVie | Phase 2 | 52 |
| Adalimumab | AbbVie | Approved | 85 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| Adalimumab | AbbVie | Pre-clinical | 23 |
| infliximab + Placebo | Merck | Phase 3 | 77 |
| Infliximab | Merck | Approved | 85 |
| Infliximab + Placebo + Naproxen | Merck | Phase 3 | 77 |
| Infliximab | Merck | Pre-clinical | 23 |
| Golimumab | Merck | Approved | 85 |
| Remicade | Merck | Approved | 85 |
| Remicade | Merck | Approved | 85 |